A Hybrid Symposium on Integrated Phase I Trial Solutions For Emerging Biopharma’s
Veeda recently concluded its Hybrid Symposium on Integrated Phase I Trial Solutions, for Emerging Biopharmas; Addressing Development Challenges, and Accelerating Timelines. In collaboration with the esteemed AIC-CCMB (Atal Incubation Centre - Centre for Cellular and Molecular Biology), this symposium brought together industry leaders, researchers, and experts to explore strategies for accelerating development timelines and overcoming obstacles in the New Chemical Entity (NCE), NBEs & Biosimilar development.
SHIMADZU and SPINCO
Group awarded Veeda as "MS Excellence in BABE Services, Largest Indian CRO" in the Shimadzu MS community meet.
Veeda Bioanalytical team had a great opportunity to participate in a poster presentation on the topic "Simultaneous Determination of (20 Amino Acids) Alanine, Arginine, Asparagine, Aspartic acid, Glutamic acid, Glutamine, Glycine, Histidine, Isoleucine, Leucine, Lysine, Methionine, Ornithine, Phenylalanine, Proline, Serine, Threonine, Tryptophan, Tyrosine, and Valine in K3EDTA Human Plasma by using LC-ESI-MS/MS " and a scientific panel discussion delivered by Dr. Vikas Trivedi on the topic "Bioanalysis of New Chemical Entities (NCE): Challenges and Case Studies," which was followed by a Q&A session
BIOSIMILAR CONCLAVE 2019
“STRATEGIES FOR SUCCESSFUL BIOSIMILAR DEVELOPMENT - BENCH TO BEDSIDE”
31 May 2019 | Novotel, Ahmedabad, India.
Biosimilar conclave 2019, an initiative by Veeda Clinical Research to bring pharma and biotech companies at a common platform which will address issues around biosimilar development & characterization, challenges of establishing bio similarity, global regulatory pathways, clinical program and commercialization strategies.
This national level conclave welcomes all the stakeholders and researchers to share their experiences and views on strategies for successful Biosimilar development, its approval and commercialization.
